Consensus on the safety management of anti-angiogenic tyrosine kinase inhibitors in bone and soft tissue sarcoma treatment / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 163-171, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-861544
ABSTRACT
Anti-angiogenesis-targeted drugs, especially anti-angiogenic tyrosine kinase inhibitors (aa-TKIs), are broadly used in the treatment of advanced bone and soft tissue sarcoma. The antitumor effects of Chinese domestically developed aa-TKIs, such as apatinib and anlotinib, were also demonstrated in several single-center or multi-center clinical studies. However, treatment-related adverse events (AEs) have limited the use of aa-TKIs. On Aug 30, 2019, the members of the Chinese Sarcoma Study Group conducted a thorough discussion on this issue and reached a consensus, focusing on the classification and treatment of common AEs that may occur during the use of aa-TKIs. The aim of this article is to improve our understanding and provide AE management guidance for clinicians as well as benefit patients using aa-TKIs.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Ensayo Clínico Controlado
/
Guía de Práctica Clínica
Idioma:
Chino
Revista:
Chinese Journal of Clinical Oncology
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS